ZURICH (Reuters) - Actelion's experimental lung drug macitentan prolonged overall survival by more than a third according to detailed study data, which the company hopes will convince investors it has a viable follow-up product to secure its commercial future. Europe's largest standalone biotech company wants the drug, which treats pulmonary arterial hypertension -- a disease that causes high blood pressure in the arteries of the lungs -- to replace blockbuster Tracleer. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment